Premium
A 2‐Year‐Old Girl with Stevens–Johnson Syndrome/Toxic Epidermal Necrolysis Treated with Intravenous Immunoglobulin
Author(s) -
Arca Ercan,
Köse Osman,
Erbil A. Hakan,
Nişancı Mustafa,
Akar Ahmet,
Gür Ali Rıza
Publication year - 2005
Publication title -
pediatric dermatology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.542
H-Index - 73
eISSN - 1525-1470
pISSN - 0736-8046
DOI - 10.1111/j.1525-1470.2005.22407.x
Subject(s) - toxic epidermal necrolysis , medicine , dermatology , plasmapheresis , erythroderma , thalidomide , intravenous immunoglobulin therapy , total body surface area , cyclophosphamide , antibody , surgery , immunology , chemotherapy , multiple myeloma
Toxic epidermal necrolysis and Stevens–Johnson syndrome are severe skin reactions, usually to drugs, associated with a widespread destruction of the epidermis. Widespread purpuric macules and epidermal detachment of less than 10% of the body surface is indicative of Stevens–Johnson syndrome, whereas epidermal detachment between 10% and 30% is called Stevens–Johnson‐toxic epidermal necrolysis overlap. Epidermal detachment involving more than 30% of the total body surface is designated as toxic epidermal necrolysis. These generalized reactions are known to occur in association with various drugs. Treatment is primarily supportive care, and there are no specific therapy regimens. Therapeutic modalities such as corticosteroids, cyclosporin, thalidomide, cyclophosphamide, and plasmapheresis, usually based on a symptomatic approach, have been tried in single patients or in small series. Intravenous immunoglobulin has recently been shown to provide rapid improvement in all three of these skin reactions. We report a 2‐year‐old girl who developed Stevens–Johnson syndrome‐toxic epidermal necrolysis overlap after receiving ampicillin‐sulbactam for an upper respiratory tract infection. She was treated successfully with a 4‐day course of intravenous immunoglobulin.